Compare Recursion Pharmaceuticals Inc (RXRX) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Skyworks Solutions Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.3 (market cap $1.81B), while Skyworks Solutions Inc trades at $68.59 (market cap $10.28B). The key difference: Skyworks Solutions Inc is far larger — about 5.7× Recursion Pharmaceuticals Inc's market cap, and Skyworks Solutions Inc pays a 4.13% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | SWKS | |
|---|---|---|
Market Cap | $1.81B | $10.28B |
Sector | Health | Technology |
52-Week High | $6.79 | $83.40 |
52-Week Low | $2.84 | $52.50 |
Enterprise Value | $1.33B | $10.16B |
Dividend Yield | — | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.
Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.
Skyworks Solutions (SWKS) trades at $68.17, down 0.9% today, with a bullish technical signal from moving averages and recent earnings beats in Q2 2026. The stock shows strong institutional buying interest and a 58% analyst buy rating, though revenue has declined from $5.5B in 2022 to $4.1B in 2025. The pending Qorvo combination and AI data center growth present strategic opportunities, but profitability margins have compressed, and a legal investigation adds near-term uncertainty.
The outlook is cautiously optimistic, supported by earnings consistency and diversification into automotive and AI markets, but investors face risks from integration execution, margin pressure, and regulatory scrutiny. The consensus price target of $66 suggests limited upside, requiring careful monitoring of merger progress and quarterly performance against expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
